GSK PLC Sponsored ADR $GSK Shares Acquired by Ethic Inc.

Ethic Inc. grew its position in GSK PLC Sponsored ADR (NYSE:GSK) by 13.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 159,588 shares of the pharmaceutical company’s stock after purchasing an additional 18,499 shares during the quarter. Ethic Inc.’s holdings in GSK were worth $6,157,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. HHM Wealth Advisors LLC raised its holdings in shares of GSK by 222.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 460 shares in the last quarter. Costello Asset Management INC acquired a new stake in shares of GSK in the 1st quarter valued at $31,000. Richardson Financial Services Inc. raised its holdings in shares of GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company’s stock valued at $33,000 after purchasing an additional 472 shares in the last quarter. SOA Wealth Advisors LLC. raised its stake in GSK by 252.1% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 605 shares in the last quarter. Finally, Olde Wealth Management LLC acquired a new stake in GSK during the 1st quarter worth $36,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Price Performance

Shares of NYSE:GSK opened at $44.21 on Thursday. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The firm has a market capitalization of $89.87 billion, a P/E ratio of 20.47, a P/E/G ratio of 1.98 and a beta of 0.53. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $45.59. The company’s fifty day moving average price is $41.31 and its 200 day moving average price is $39.16.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.11. The company had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. GSK’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, sell-side analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 9th. Shareholders of record on Friday, August 15th were paid a $0.4206 dividend. The ex-dividend date was Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a yield of 3.8%. GSK’s payout ratio is currently 78.24%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on GSK shares. Wall Street Zen upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of GSK in a research note on Wednesday, October 8th. Seven investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.